ID

34205

Description

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01326000

Link

https://clinicaltrials.gov/show/NCT01326000

Keywords

  1. 1/15/19 1/15/19 -
  2. 5/14/19 5/14/19 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 15, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Cancer NCT01326000

Eligibility Colorectal Cancer NCT01326000

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Description

ID.1

Data type

boolean

carcinoma of the colon and/or rectum
Description

ID.2

Data type

boolean

disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
Description

ID.3

Data type

boolean

ecog performance status 0-1
Description

ID.4

Data type

boolean

adequate hematological, renal and liver function
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
Description

ID.6

Data type

boolean

prior treatment with irinotecan
Description

ID.7

Data type

boolean

radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
Description

ID.8

Data type

boolean

cns metastasis
Description

ID.9

Data type

boolean

history of or active autoimmune disorders/conditions
Description

ID.10

Data type

boolean

Similar models

Eligibility Colorectal Cancer NCT01326000

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
adult patients, >/= 18 years of age
boolean
ID.2
Item
carcinoma of the colon and/or rectum
boolean
ID.3
Item
disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
boolean
ID.4
Item
ecog performance status 0-1
boolean
ID.5
Item
adequate hematological, renal and liver function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
boolean
ID.7
Item
prior treatment with irinotecan
boolean
ID.8
Item
radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
boolean
ID.9
Item
cns metastasis
boolean
ID.10
Item
history of or active autoimmune disorders/conditions
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial